Barchart on MSN2d
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
FierceBiotech28d
Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...
The Business Journals27d
Cambridge biotech's layoffs will cut dozens of Mass. employees
In a filing Friday, it said how many of those cut are Massachusetts workers ... s Disease expected later this year. Sage and Biogen Inc. (Nasdaq: BIIB) co-developed zuranolone, which is sold ...
pharmaphorum1y
Biogen taps Envisagenics' AI to speed up RNA splicing R&D
Biogen has made a further push into RNA-based ... data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA ...
Business Insider1mon
Biogen’s Strategic Shift: Felzartamab’s Promise in IgAN and Beyond Fuels Buy Rating
Begin your TipRanks Premium journey today. Biogen (BIIB) Company Description: Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops ...
Nasdaq1mon
Biogen's Q3 2024 Earnings: What to Expect
Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...
Seeking Alpha27d
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...
Yahoo Finance29d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Massachusetts-based company said Wednesday in a statement. While that’s a 6% decline from a year earlier, it beat analysts’ estimates. The results could help Biogen start to restore investor ...
CNN1y
Biogen Inc.
Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.